



VIA HAND DELIVERY DECEMBER 10, 2002

1642

THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
He, et al.

Docket No.: PF150D2

RECEIVED

DEC 12 2002

Application No.: 10/021,002

Group Art Unit: 1642

TECH CENTER 1600/290

Filed: December 9, 2001

Examiner: Unassigned

#8

For: **Human Prostatic Specific Reductase**

**REQUEST FOR CORRECTED PUBLICATION UNDER 37 C.F.R. § 1.221(b)
DUE TO MATERIAL OFFICE MISTAKE**

Box PGPUB
Commissioner for Patents
Washington, D.C. 20231

RECEIVED

DEC 18 2002

GROUP 3600

Sir:

Applicants respectfully request a corrected publication of the above-listed application pursuant to 37 C.F.R. § 1.221(b) due to a material mistake made by the U.S. Patent and Trademark Office. In particular, the publication (US 2002/0150578 A1) improperly lists the filing date and the Application Serial Number of the International Application to which the instant application claims benefit under 35 U.S.C. § 119(e).

The above mistake is apparent from Office records, as the Application Data Sheet and the first paragraph of the present application each contain the correct serial number and date of priority application. A copy of the first page of the published priority application is attached as Exhibit A. Moreover, the above mistake is material, because the improper priority claim affects the identification of the correct PCT priority application and use of the published application as prior art under 35 U.S.C. § 102(e). In particular, without the correct date for the priority application being listed, an examiner or member of the public would be unable to determine the correct effective date of the publication as a reference for at least some of the subject matter


disclosed therein. In order to make such a determination from the present publication, an examiner or member of the public would first be forced to obtain the correct priority information from the Office, thus undermining the use of the publication (and published applications in general) for § 102(e) purposes.

Accordingly, Applicants respectfully request that a corrected publication of the above-listed application be made pursuant to 37 C.F.R. § 1.221(b).

No fee is believed due for this submission. In the event that a fee is required in connection with this submission, please charge the required fee to Deposit Account No. 08-3425.


Dated: December 10, 2002

Respectfully submitted,

By 
Lin J. Hymel

Registration No.: 45,414
HUMAN GENOME SCIENCES, INC.
9410 Key West Avenue
Rockville, Maryland 20850
(301) 251-6015
Attorneys for Applicant

KKH/LJH/FR/ba



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Approved for use through 10/31/2002. OMB 0651-0032

PTO/SB/17 (10-02)

FEE TRANSMITTAL for FY 2003

Patent fees are subject to annual revision.

☐ Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$) 0.00

Complete if Known

Application Number 10/021,002-Conf. #9797
Filing Date December 19, 2001
First Named Inventor Wei-Wu He
Examiner Name Not Yet Assigned
Group Art Unit 1642
Attorney Docket No. PF150D2

METHOD OF PAYMENT (check all that apply)

☐ Check ☐ Credit Card ☐ Money Order ☐ Other ☐ None
☐ Deposit Account

Deposit Account Number

08-3425

Deposit Account Name

Human Genome Sciences, Inc.

The Commissioner is hereby authorized to: (check all that apply)

☐ Charge fee(s) indicated below ☒ Credit any overpayments

☒ Charge any additional fee(s) during the pendency of this application

☐ Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.

FEE CALCULATION

1. BASIC FILING FEE

Large Entity Small Entity

Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee Description	Fee Paid
1001	740	2001	370	Utility filing fee	
1002	330	2002	165	Design filing fee	
1003	510	2003	255	Plant filing fee	
1004	740	2004	370	Reissue filing fee	
1005	160	2005	80	Provisional filing fee	

SUBTOTAL (1) (\$) 0.00

2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE

Total Claims -20** = x =
Independent Claims -3** = x =
Multiple Dependent =

Large Entity Small Entity

Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee Description
1202	18	2202	9	Claims in excess of 20
1201	84	2201	42	Independent claims in excess of 3
1203	280	2203	140	Multiple dependent claim, if not paid
1204	84	2204	42	** Reissue independent claims over original patent
1205	18	2205	9	** Reissue claims in excess of 20 and over original patent

SUBTOTAL (2) (\$) 0.00

**or number previously paid, if greater; For Reissues, see above

FEE CALCULATION (continued)

3. ADDITIONAL FEES

Large Entity Small Entity

Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee Description
1051	130	2051	65	Surcharge - late filing fee or oath
1052	50	2052	25	Surcharge - late provisional filing fee or cover sheet
1053	130	1053	130	Non-English specification
1812	2,520	1812	2,520	For filing a request for ex parte reexamination
1804	920*	1804	920*	Requesting publication of SIR prior to Examiner action
1805	1,840*	1805	1,840*	Requesting publication of SIR after Examiner action
1251	110	2251	55	Extension for reply within first month
1252	400	2252	200	Extension for reply within second month
1253	920	2253	460	Extension for reply within third month
1254	1,440	2254	720	Extension for reply within fourth month
1255	1,960	2255	980	Extension for reply within fifth month
1401	320	2401	160	Notice of Appeal
1402	320	2402	160	Filing a brief in support of an appeal
1403	280	2403	140	Request for oral hearing
1451	1,510	1451	1,510	Petition to institute a public use proceeding
1452	110	2452	55	Petition to revive - unavoidable
1453	1,280	2453	640	Petition to revive - unintentional
1501	1,280	2501	640	Utility issue fee (or reissue)
1502	460	2502	230	Design issue fee
1503	620	2503	310	Plant issue fee
1460	130	1460	130	Petitions to the Commissioner
1807	50	1807	50	Processing fee under 37 CFR 1.17(q)
1806	180	1806	180	Submission of Information Disclosure Stmt
8021	40	8021	40	Recording each patent assignment per property (times number of properties)
1809	740	2809	370	Filing a submission after final rejection (37 CFR 1.129(a))
1810	740	2810	370	For each additional invention to be examined (37CFR 1.129(b))
1801	740	2801	370	Request for Continued Examination (RCE)
1802	900	1802	900	Request for expedited examination of a design application

Other fee (specify) _____

*Reduced by Basic Filing Fee Paid

SUBTOTAL (3) (\$) 0.00

SUBMITTED BY

Name (Print/Type) Lin J. Hymel

Registration No. (Attorney/Agent)

45,414

Complete (if applicable)

Telephone (301) 251-6015

Signature

Lin J. Hymel

Date

December 10, 2002

RECEIVED
DEC 18 2002
GROUP 3600

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

Exhibit A

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 1/21, 5/10, 9/02, 15/10, 15/11, 15/12, 15/53, 15/63, C07K 14/47, C12Q 1/68, 1/26	A1	(11) International Publication Number: WO 96/22360 (43) International Publication Date: 25 July 1996 (25.07.96)
(21) International Application Number: PCT/US95/01827 (22) International Filing Date: 20 January 1995 (20.01.95) (71) Applicant (for all designated States except US): HUMAN GENOME SCIENCES, INC. [US/US]; 9410 Key West Avenue, Rockville, MD 20850-3338 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): HE, Wei, Wu [CN/US]; 6225 Free Stone Court, Columbia, MD 21045 (US). MEISSNER, Paul, S. [US/US]; 18040 Barnesville Road, P.O. Box 306, Barnesville, MD 20838 (US). HUDSON, Peter, L. [US/US]; 19041 Highstream Drive, Germantown, MD 20874 (US). ROSEN, Craig, A. [US/US]; 22400 Rolling Hill Road, Laytonsville, MD 20882 (US). (74) Agents: OLSTEIN, Elliot, M., et al.; Carella, Byrne, Bain, Gilfillan, Cecchi, Stewart & Olstein, 6 Becker Farm Road, Roseland, NJ 07068 (US).		(81) Designated States: AU, CA, CN, JP, KR, MX, NZ, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published With international search report.
(54) Title: HUMAN PROSTATIC SPECIFIC REDUCTASE (57) Abstract <p>A human prostatic specific reductase polypeptide and polynucleotides encoding such polypeptide and a procedure for producing such polypeptide by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polynucleotides as a diagnostic marker for prostate cancer and as an agent to determine if the prostate cancer has metastasized. Also disclosed are antibodies specific to the prostatic specific reductase polypeptide which may be used to target prostate cancer cells and be used as part of a prostate cancer vaccine. Methods of screening for agonists and antagonists for the polypeptide and therapeutic uses of the antagonists are also disclosed.</p>		